Study of AKR-501 Tablets Taken Orally Once Daily for 28 Days in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP)
Public ClinicalTrials.gov record NCT00441090. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Double-Blind, Randomized, Dose-Ranging, Placebo-Controlled, Parallel Group Study of AKR-501 Tablets Taken Orally Once Daily for 28 Days in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP).
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine the efficacy, safety and tolerability, of AKR-501 (avatrombopag) tablets, as compared to placebo, in the treatment of participants with chronic Idiopathic Thrombocytopenic Purpura (ITP).
Study identification
- NCT ID
- NCT00441090
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 64 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 2007 (Type not available)
- Primary completion
- Jan 2009 (Actual)
- Completion
- Jun 2009 (Actual)
- Last update posted
- Mar 7, 2018
2007 – 2009
United States locations
- U.S. sites
- 25
- U.S. states
- 17
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pacific Cancer Medical Center, Inc | Anaheim | California | 92801 | — |
| Comprehensive Blood and Cancer Center | Bakersfield | California | 93309 | — |
| Bay Area Cancer Research Group, LLC | Concord | California | — | — |
| Pacific Coast Hematology/Oncology Medical Group Inc. | Fountain Valley | California | 92708 | — |
| University of California Irvine Cancer Center | Orange | California | 92618 | — |
| Davis, Posteraro and Wasser, MDs, LLP | Manchester | Connecticut | 06105 | — |
| Georgetown University | Washington D.C. | District of Columbia | — | — |
| Florida Cancer Institute | New Port Richey | Florida | 34655 | — |
| Columbus Clinic, PC | Columbus | Georgia | 31901 | — |
| John H. Stroger, Jr. Hospital of Cook County, Div. of Hematology and Oncology | Chicago | Illinois | 60612 | — |
| Comprehensive Bleeding Disorders Center | Peoria | Illinois | 61614 | — |
| Cancer Care Center, Inc. | New Albany | Indiana | 47150 | — |
| Johns Hopkins University | Baltimore | Maryland | 21287 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Capitol Comprehensive Cancer Care Clinic | Jefferson City | Missouri | 65109 | — |
| Kansas City Cancer Center, LLC | Kansas City | Missouri | 64131 | — |
| UMDNJ - Robert Wood Johnson Medical School | New Brunswick | New Jersey | 08901 | — |
| Mount Sinai Medical Center | New York | New York | 10029 | — |
| New York Presbyterian Hospital, Weill Medical College of Cornell University | New York | New York | 10032 | — |
| Emerywood Oncology and Hematology | High Point | North Carolina | 27262 | — |
| Mid Ohio Oncology/Hematology, Inc., dba The Mark H. Zangmeister Center | Columbus | Ohio | 43219 | — |
| UPENN | Philadelphia | Pennsylvania | 19104 | — |
| Western Pennsylvania Hospital | Pittsburgh | Pennsylvania | 15212 | — |
| Cancer Centers of the Carolina | Greenville | South Carolina | 29605 | — |
| Puget Sound Blood Center | Seattle | Washington | 98014 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00441090, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 7, 2018 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00441090 live on ClinicalTrials.gov.